Cargando…

Immune responses to SARS‐CoV‐2 vaccination in multiple sclerosis: a systematic review/meta‐analysis

INTRODUCTION: Responses to SARS‐CoV‐2 vaccination in patients with MS (pwMS) varies by disease‐modifying therapies (DMTs). We perform a meta‐analysis and systematic review of immune response to SARS‐CoV‐2 vaccines in pwMS. METHODS: Two independent reviewers searched PubMed, Google Scholar, and Embas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gombolay, Grace Y., Dutt, Monideep, Tyor, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349877/ https://www.ncbi.nlm.nih.gov/pubmed/35852423 http://dx.doi.org/10.1002/acn3.51628

Ejemplares similares

240 Neurologic complications in children with seizures and respiratory illness: A comparison between SARS-CoV-2 and other respiratory viruses
por: Gombolay, Grace, et al.
Publicado: (2022)

Neurological Complications in Children Hospitalized With Seizures and Respiratory Infections: A Comparison Between SARS-CoV-2 and Other Respiratory Infections
por: Gombolay, Grace, et al.
Publicado: (2022)

Antibody response to SARS-CoV-2 vaccination or infection in a prospective cohort of children with neuroinflammatory diseases
por: Kaufmann, Charlotte, et al.
Publicado: (2023)

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
por: Sellner, Johann, et al.
Publicado: (2021)

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
por: Woopen, Christina, et al.
Publicado: (2021)

Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination
por: Faissner, Simon, et al.
Publicado: (2022)

Vaccine Hesitancy in Patients With Multiple Sclerosis: Preparing for the SARS-CoV-2 Vaccination Challenge
por: Diem, Lara, et al.
Publicado: (2021)

Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity
por: Sabatino, Joseph J., et al.
Publicado: (2021)

Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
por: Sabatino, Joseph J., et al.
Publicado: (2022)

SARS-CoV-2 vaccines tolerability: A perspective by people with multiple sclerosis
por: Di Filippo, Massimiliano, et al.
Publicado: (2022)

Multiple sclerosis following SARS-CoV-2 infection
por: Palao, M., et al.
Publicado: (2020)

SARS-CoV-2 triggered relapse of multiple sclerosis
por: Finsterer, Josef
Publicado: (2022)

Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus
por: Centonze, Diego, et al.
Publicado: (2021)

Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis
por: Gyang, Tirisham V., et al.
Publicado: (2022)

Response to SARS-CoV-2 vaccination in multiple sclerosis patients on disease modifying therapies
por: Allman, M., et al.
Publicado: (2022)

Predictors for insufficient SARS-CoV-2 vaccination response upon treatment in multiple sclerosis
por: Schraad, Muriel, et al.
Publicado: (2022)

A Case of Multiple Sclerosis Uncovered Following Moderna SARS-CoV-2 Vaccination
por: Ahoussougbemey Mele, Ange, et al.
Publicado: (2022)

SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
por: Cree, Bruce A. C., et al.
Publicado: (2023)

Seeing the T cell Immunity of SARS-CoV-2 and SARS-CoV: Believing the Epitope-Oriented Vaccines
por: Yue, Can, et al.
Publicado: (2023)

Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis
por: Pompsch, Mosche, et al.
Publicado: (2021)

Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies
por: Drulovic, Jelena, et al.
Publicado: (2021)

Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
por: Meca-Lallana, Virginia, et al.
Publicado: (2023)

Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis
por: Breu, Markus, et al.
Publicado: (2023)

Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption
por: Gröning, Remigius, et al.
Publicado: (2023)

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
por: Cohen, Jeffrey A, et al.
Publicado: (2022)

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
por: Liu, William J., et al.
Publicado: (2017)

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

SARS-CoV-2 Vaccines: The Mucosal Immunity Imperative
por: Adashi, Eli Y., et al.
Publicado: (2022)

The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies
por: Molaei, Soheila, et al.
Publicado: (2021)

Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?
por: Bellucci, Gianmarco, et al.
Publicado: (2021)

SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis
por: Diaz de la Fe, Amado, et al.
Publicado: (2021)

SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis()
por: Piñar Morales, R., et al.
Publicado: (2021)

SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation
por: MacDougall, Madison, et al.
Publicado: (2022)

Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab
por: Katz, J.D., et al.
Publicado: (2022)

Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
por: Pugliatti, Maura, et al.
Publicado: (2022)

T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
por: Wolf, Asia-Sophia, et al.
Publicado: (2023)

Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis()
por: Novak, Frederik, et al.
Publicado: (2021)

Ocrelizumab Concentration Is a Good Predictor of SARS‐CoV‐2 Vaccination Response in Patients with Multiple Sclerosis
por: van Kempen, Zoé L. E., et al.
Publicado: (2022)

SARS-CoV-2 Variants, Vaccines, and Host Immunity
por: Mistry, Priyal, et al.
Publicado: (2022)

Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
por: Gadani, Sachin P., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_86vmo5blu5nkvrev1jfdqvu73c